Document:

exhibit10_1.htm

EXHIBIT 10.1

 

EXECUTIVE EMPLOYMENT AGREEMENT

This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of July 5, 2011 (the Effective Date”), by and between POZEN Inc. (the “Company”), with offices located at Suite 400, 1414 Raleigh Road, Chapel Hill, North Carolina 27517, and Tomás S. Bocanegra, M.D, F.A.C.P, F.A.C.R. (“Executive”), whose address is 1061 Lawrence Avenue,

Westfield, New Jersey 07090.

WITNESSETH:

WHEREAS, the Company is engaged in certain pharmaceutical research, development and marketing activities; and

WHEREAS, the Company wishes to employ Executive in the position of Executive Vice President, Development, and Executive wishes to accept such employment with the Company.

NOW, THEREFORE, in consideration of the foregoing and the provisions and mutual promises herein contained and other good and valuable consideration, the parties hereby agree as follows:

1. EMPLOYMENT.  The Company hereby agrees to employ Executive, and Executive hereby agrees to accept employment with the Company, as Executive Vice President, Development of the Company reporting to the CEO or President, with such duties and responsibilities as are normally related to such position in accordance with the standards of the industry and as specified in Exhibit A, attached hereto and incorporated herein by reference, and such reasonable additional duties consistent with the position as may be assigned to Executive from time to time by the CEO or President and/or Board of Directors of the Company.

2. TERM.  Executive’s employment shall be for a term of one (1) year from the date of execution of this Agreement (the “Initial Term”), and thereafter shall be automatically renewed with additional one (1) year terms to follow consecutively, subject to the termination and severance provisions herein later provided, unless amended or modified by mutual agreement of the parties.  As used herein, “Term” shall include the Initial Term and any renewals thereof in accordance with this Agreement.

3. EXCLUSIVE SERVICE.  Executive agrees to devote Executive’s full time and attention to the performance of Executive’s duties and responsibilities on behalf of the Company.  Executive shall comply with all lawful policies and regulations of the Company and all applicable government laws, rules and regulations that are now or hereafter in effect.

4. COMPENSATION.  During the Term of this Agreement, Executive’s compensation shall be determined and paid as follows:

  

- 1 -

  

(a) Base Salary.  Executive shall receive an annual base salary of Three Hundred Eighty-five Thousand Dollars ($385,000.00) payable in accordance with the Company’s standard payroll practices and subject to applicable withholdings.  Annual increases will be made, if any, based upon performance, and in the sole discretion of the Company, such increases, if any, to be effective as may be set by the Compensation Committee of the Board of Directors by March 31 of each year during the Term.

(b) Bonus.  Executive shall be eligible to receive an annual cash incentive bonus targeted to forty percent (40%) of Executive’s annual base salary as may be set by the Company by March 31 of each year.  The determination of the actual bonus earned, if any, shall be at the sole discretion of the Company and shall be based upon the Company’s assessment of Executive’s performance and the achievement of certain objectives which shall be set by the Company from time to time. Executive’s performance shall be evaluated by the CEO or President on an annual basis, and the Compensation Committee of the Board of Directors shall set Executive’s bonus compensation in its sole discretion.  Nothing in this section shall be construed as guaranteeing Executive a bonus in any amount.  If an annual bonus is awarded, it shall be paid in the year following the year in which such bonus was earned, on or before March 15 of such year irrespective of whether Executive is still employed by the Company at that time.

(c) Stock Options.  Subject to the approval of the Compensation Committee of the Board of Directors, upon the commencement of Executive’s employment with the Company, Executive shall be granted an option to purchase one hundred thousand (100,000) shares of the common stock of the Company at an exercise price equal to the closing price of the common stock of the Company as quoted on the NASDAQ Stock Market on the date of grant, and vesting twenty-five percent (25%) annually over four years with the initial vesting date occurring on the one-year anniversary of the date of grant.  The option shall be governed by the terms of the POZEN Inc. 2010 Omnibus Equity Compensation Plan, and a stock option agreement issued in accordance therewith.  Subject to the approval of the Compensation Committee of the Board of Directors, Executive shall also be eligible to receive an annual stock option or other incentive award, with the amount and form of any such award being at an equivalent rate comparable to that of other Executive Officers and determined in the sole discretion of the Company.

(d) Benefits.  Executive shall be eligible to participate in the Company’s standard employee benefit programs made available to employees of the Company from time to time as of the first day of employment, subject to contractual terms governing such benefits, appropriate premium contributions, benefit elections, etc. and provided that Executive meets the eligibility requirements thereof.  In addition, Executive shall be entitled to three (3) weeks of paid vacation per year.

(e) Business Expenses.  The Company shall reimburse Executive for all reasonable expenses incurred in the furtherance of the Company’s business and interests, including travel and entertainment, provided that Executive complies with the expense reporting policies and procedures of the Company.

  

- 2 -

  

(f) Adequate Office Space.  The Company shall provide to Executive adequate office space, facilities, and administrative support appropriate to Executive’s position.

	
  

	
.

 

 

5. TERMINATION.  This Agreement shall or may be terminated, as the case may be, upon the terms and conditions hereinafter provided.

(a) Voluntary Termination.  This Agreement shall be considered voluntarily terminated by the parties if either party provides written notice of such party’s intent not to renew this Agreement, provided that such party shall provide at least ninety (90) days’ written notice to the other party prior to the last day of the Initial Term or any renewal term.  Voluntary termination by the Company shall entitle Executive to severance as set forth in Section 5(e) of this Agreement and forgiveness of the note referred to in Exhibit A of Exhibit C to this Agreement.

(b) Good Reason Termination.  Executive may terminate this Agreement upon written notice to the Company for Good Reason (as defined in this Agreement).  Termination by the Executive of this Agreement for Good Reason (as defined by this Agreement) shall entitle Executive to severance as set forth in Section 5(e) of this Agreement and forgiveness of the note referred to in Exhibit A of Exhibit C to this Agreement.

(c) Involuntary Termination. The Company may terminate this Agreement upon written notice to Executive (or Executive’s representative) in any of the following events:

(i)           The death of Executive;

(ii) Executive becomes permanently disabled (as defined in Section 5(g) below); or

(iii) For Cause, immediately upon written notice to Executive.  “Cause” shall be determined by the Board of Directors and shall mean:  (A) material breach by Executive of the terms of this Agreement; (B) breach of the Nondisclosure, Inventions and Non-Competition Agreement (described in Section 6 below); (C) material failure by Executive to comply with the lawful policies and/or directives of the Company or the Board of Directors; (D) any illegal or dishonest action that is materially detrimental to the Company; or (E) Executive’s failure to faithfully carry out the duties of Executive’s position, provided that Executive shall be given a period of thirty (30) days after receipt of written notice of such failure during which to correct such failure and shall have failed to do so; and (F) Executive’s violation of the Company’s policies regarding harassment or unlawful discrimination.

  

- 3 -

  

(d)           Obligations upon Certain Terminations.  Upon voluntary termination of this Agreement by the Executive pursuant to Section 5(a) of this Agreement; termination of Executive’s employment by the Company for Cause (as defined above) pursuant to Section 5(c)(iii) of this Agreement; Executive’s death or disability; or termination by Executive for other than Good Reason (as defined below), the Company shall have no further obligations hereunder other than the payment of all compensation and other benefits payable to Executive through the date of such termination, except that in the event of the Executive’s death or disability, the note referred to above in Exhibit A of Exhibit C to this Agreement shall be immediately forgiven. Such amounts due shall be paid on the Company’s next regularly scheduled payroll date unless any such amount is not then calculable, in which case payment of such amount shall be made on the first regularly scheduled payroll date after the amount is calculable but no later than March 15 of the year following the year in which the Executive’s employment terminated.

(e)           Severance.

(i)           In the event of termination of Executive’s employment (A) by the Company for reasons other than Cause or Executive’s death or disability, or (B) by Executive for Good Reason, and provided Executive executes and does not revoke a release and settlement agreement (the “Release”) in a form acceptable to the Company, Executive shall receive a severance benefit, subject to any applicable taxes and withholdings, in an amount equal to one (1) year’s base salary (the “Salary Benefit”) plus the average annual bonus awarded Executive over the previous two (2) years (the Bonus,” and, together with the Salary Benefit, the “Severance Benefit”); provided however, if such termination occurs at any time during the first two years of the Term, the amount of the Bonus shall be equal to the first year target or, if a first year bonus has been paid, equal to the average of the first year actual percentage and the second year target.  Subject to Section 5(e)(ii) below, the Company shall pay the Salary Benefit, in monthly installments, on the fifth business day of each month commencing with the second month following the month in which Executive’s termination of employment occurred. The Company shall pay the Bonus in a lump sum payment within ninety (90) days of the date of termination of Executive’s employment (the “Termination Date”), but in no event later than March 15 of the year following the year in which such termination of employment occurred, or in the event of termination pursuant to Section 5(f)(iv), no later than March 15 of the year following the year in which the Change of Control occurred.  Executive shall also continue to be entitled to receive all Company nontaxable health and other nontaxable employee benefits to which Executive was entitled as of the Termination Date, subject to the terms of all applicable benefit plans and to the extent such benefits can be provided to non-employees (or to the extent such benefits cannot be provided to non-employees, then the grossed up amount the Company was paying for those benefits immediately prior to the Termination Date), at the same average level and on the same terms and conditions which applied immediately prior to the Termination Date, for the shorter of (i) one year following the date of such Termination Date or (ii) until Executive obtains comparable coverage from another employer (the “Continuing Benefits”).

  

- 4 -

  

(ii)           Notwithstanding the foregoing, if Executive is on the termination date a “specified employee” (as defined in Section 409A of the Internal Revenue Code, as amended (the “Code”) and the regulations promulgated under such Section 409A (“Code Section 409A”) and as determined in accordance with the permissible method then in use by the Company, or, if none, in accordance with the applicable default provisions of Code Section 409A, relating to “specified employees”), then if and to the extent required in order to avoid the imposition on Executive of any excise tax under Code Section 409A, the payment of any Severance Benefit, Continuing Benefits or other payments under this Section 5 shall not commence until, and shall be made on, the first business day after the date that is six (6) months following the Termination Date, and in such event the initial payment shall include a catch-up amount covering amounts that would otherwise have been paid during the six-month period following the Termination Date.

(f)           Good Reason.  For purposes of this Agreement, “Good Reason” shall mean, the occurrence, without the consent of Executive, of any of the following events, unless, in the case of (i), (ii) and (iii) below, such event is corrected within thirty (30) days after written notification by Executive to the Company of the same: (i) the office from which Executive performs Executive’s principal duties is moved more than fifty (50) miles from the current location of the Company’s offices in Chapel Hill, North Carolina; (ii) Executive’s duties and responsibilities are substantially reduced or diminished; or his position otherwise materially altered; (iii) the Company materially breaches its obligations under this Agreement; or (iv) a Change of Control (as defined below) occurs and Executive notifies the Company in writing within sixty (60) days of the consummation of such Change of Control that Executive intends to terminate Executive’s employment as a result of the Change of Control, in which event such termination shall be effective not less than sixty (60) days after the date of such written notice.

 

(g)           Disability.  For purposes of this Agreement, Executive shall be considered permanently disabled when a qualified medical doctor mutually acceptable to the Company and Executive or Executive’s personal representative shall have certified in writing that:  (i) Executive is unable because of medically determinable physical or mental disability to perform substantially all of Executive’s duties for more than one hundred eighty (180) calendar days measured from the last full day of work; or (ii) by reason of mental or physical disability, it is unlikely that Executive will be able, within one hundred eighty (180) calendar days, to resume substantially all business duties and responsibilities in which Executive was previously engaged and otherwise discharge Executive’s duties under this Agreement.

(h)           Change of Control.  For purposes of this Agreement, a “Change of Control” shall be deemed to have occurred:

  

- 5 -

  

(i)           If any person (as such term is used in sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) (other than the Company or any trustee or fiduciary holding securities under an employee benefit plan of the Company) becomes a beneficial owner (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than 50% of the voting power of the then outstanding securities of the Company; provided that a Change of Control shall not be deemed to occur as a result of a transaction in which the Company becomes a subsidiary of another corporation and in which the stockholders of the Company, immediately prior to the transaction, will beneficially own, immediately after the transaction, shares entitling such stockholders to more than 50% of all votes to which all stockholders of the parent corporation would be entitled in the election of directors (without consideration of the rights of any class of stock to elect directors by a separate class vote); or

(ii)           Upon the consummation of (A) a merger or consolidation of the Company with another corporation where the stockholders of the Company, immediately prior to the merger or consolidation, will not beneficially own, immediately after the merger or consolidation, shares entitling such stockholders to more than 50% of all votes to which all stockholders of the surviving corporation would be entitled in the election of directors (without consideration of the rights of any class of stock to elect directors by a separate class vote), or (B) a sale or other disposition of all or substantially all of the assets of the Company.

6. NON-DISCLOSURE, INVENTIONS AND NON COMPETITION.  Executive acknowledges that Executive has executed and agrees to continue to be bound by the terms of the Company’s standard non-disclosure, inventions and non-competition agreement in the form attached hereto as Exhibit B and that such terms are incorporated herein by reference and made a material part of this Agreement (the “Nondisclosure Agreement”).

7. NOTICES.  Any notice required to be given hereunder shall be sufficient if in writing, and sent by certified or registered mail, return receipt requested, first-class postage prepaid, in the case of Employee, to his address as shown on Employer’s records, and in the case of Employer, to its principal office in the State of North Carolina.

8. SEVERABILITY.  The provisions of this Agreement shall be deemed severable, and the invalidity or unenforceability of any provision (or part thereof) of this Agreement shall in no way affect the validity or enforceability of any other provision (or remaining part thereof).

9. GOVERNING LAW.  This Agreement shall be governed by and construed according to the laws of the State of North Carolina, without reference to the choice of law provisions of such laws.

  

- 6 -

  

10. ENTIRE AGREEMENT.  This Agreement and the Nondisclosure Agreement (including any exhibits or schedules hereto or thereto) contain the entire agreement of the parties relating to the subject matter hereof, and the parties hereto have made no agreements, representations, or warranties relating to the subject matter of this Agreement which are not set forth herein or therein.  In particular, without limiting the foregoing, this Agreement supersedes the offer letter from the Company to Executive dated May 27, 2011, attached hereto as Exhibit C, except for paragraphs 4-7 of Exhibit A of the attached Exhibit C.  No modification of this Agreement shall be valid unless made in writing and signed by the parties hereto.

11.           BENEFIT.  This Agreement shall be binding upon and inure to the benefit of both parties and their respective heirs, representatives, successors and assigns, including any corporation or other entity with which or into which the Company may be merged or which may succeed to its assets or business; provided, however, that the obligations of Executive are personal and shall not be assigned by Executive.

12.           EXECUTIVE REPRESENTATIONS.

(a)           Executive represents that his performance of this Agreement and as an employee of the Company does not and will not breach any employment, non-competition or other agreement to keep confidential any confidential or proprietary information acquired by Executive in confidence or in trust prior to Executive’s employment by the Company.  Executive represents that he has not entered into, and agrees not to enter into, any agreement that conflicts with or violates this Agreement or would prevent or interfere with the Company’s employment of Executive on the terms set forth herein.

(b)           Executive represents that he has not brought and shall not use in the performance of Executive's responsibilities for the Company, any materials or documents of a former employer which are not generally available to the public or which did not belong to Executive prior to Executive’s employment with the Company, unless Executive has obtained written authorization from the former employer or other owner for their possession and use and provided the Company with a copy thereof.

13.           INJUNCTIVE RELIEF.  Executive understands and agrees that the Company may suffer irreparable harm in the event that Executive breaches any of Executive’s obligations under this Agreement and that monetary damages may be inadequate to compensate the Company for such breach.  Accordingly, Executive agrees that, in the event of a breach or threatened breach by Executive of any of the provisions of this Agreement, the Company, in addition to and not in limitation of any other rights, remedies, or damages available to the Company at law or in equity, may be entitled to seek a permanent injunction in order to prevent or to restrain any such breach by Executive, or by Executive’s partners, agents, representatives, servants, employers, employees and/or any and all persons directly or indirectly acting for or with Executive; provided such injunction shall not affect Executive’s ownership rights in the Company or compensation earned or due Executive.

[Signature page follows]

  

- 7 -

  

IN WITNESS WHEREOF, the parties hereto have executed this Executive Employment Agreement and affixed their seals as of the day and year first above written.

	  	
EMPLOYER:

	  	  	  
	  	
POZEN INC.

	  	  	  
	  	
By:

	  
	  	
Name:

	
John R. Plachetka, Pharm.D.

	  	
Title:

	
Chairman, President and CEO

	  	  	  
	  	
EMPLOYEE:

	  	  	  
	  	  	
Tomás S. Bocanegra, M.D, F.A.C.P, F.A.C.R.

	  	  	  
	  	  	  

  

- 8 -

  

Exhibit A

Key Responsibilities and Standards of Performance

Executive Vice President, Development

POZEN, Inc

	
Weight

	
Responsibility

List the primary responsibilities, duties, or tasks that are required of this position.

	
Standard of Performance

This is the basis for measurement. List the actions needed to perform this function accurately in order to succeed.

	
Knowledge,Skills,Abilities

List the specific competencies required for successful job performance.

	
40

 

	
Manage product development activities

- Supervise

       - Toxicology

       - Product Development

       - Clinical Operations

       - Biostatistics

       - Regulatory Affairs

 

	
1. All activities performed on time, on budget , and according to GCP/GLP/GMP and FDA and other regulatory standards

2. No unavoidable surprises to CEO or BOD

3. All activities performed within corporate guidelines and development plans

4. All regulatory submissions should be well constructed, strategically consistent with corporate philosophy, and likely to meet approval of regulators (FDA, etc)

5. Employees supervised in a manner consistent with corporate philosophy and culture

6. Performance reviews completed on time and with appropriate actions

 

	
1. Knowledge of US and European registration processes and requirements

2. Knowledge of all phases and aspects of drug development

3. Personnel and project management skills

4. Interpersonal and communication skills adequate for internal and external business relationships

	
20

 

	
Create, update and manage product development plans for each project

	
1. Define clinical indication and target profile sufficient for registration and partnering

2. Develop registration strategy for US and Europe for approval by CEO or BOD

3. With the CEO and other members of the senior staff, identify go/no go decision points

4. Establish and revise, as appropriate, activities, budgets and timelines for each project to achieve corporate objectives

5. Maintain corporate infrastructure to successfully execute development activities (using the POZEN outsource model) consistent with achieving corporate objectives and goals

	
1. Knowledge of US and European registration

2. Knowledge of competitive product attributes

3. Knowledge of clinical, nonclinical, and pharmaceutical drug development processes

  

- 9 -

  

	
Weight

	
Responsibility

List the primary responsibilities, duties, or tasks that are required of this position.

	
Standard of Performance

This is the basis for measurement. List the actions needed to perform this function accurately in order to succeed.

	
Knowledge,Skills,Abilities

List the specific competencies required for successful job performance.

	
20

	
Review and approve all documents subject to regulatory and medical review

	
1. Clinical protocols contain rationale for dosage selection, objectives, procedures, statistical analyses and entry criteria that will optimize recruitment and achieve the objectives of the development plan in a timely and cost effective manner

2. Study reports are completed in a timely fashion, succinctly according to ICH/FDA guidelines, and in keeping with corporate strategy for content and submission

3. All FDA communications and regulatory submissions are drafted and approved at the appropriate level prior to submission

4. Templates, SOPs, internal guidelines and standards are instituted and maintained as needed and in a manner that enhances consistency and compliance

	
1. Knowledge of clinical research and statistical techniques

2. Knowledge of regulatory review and approval requirements

	
20

 

	
Support Investor Relations and Business Development

	
1. Provide Product Development recommendation on in-license candidates in a timely and professional manner and consistent with corporate objectives and philosophy

2. Provide product specific presentations to prospective commercial partners in a professional manner consistent with corporate objectives

3. Approve press releases accurately describing the results of POZEN studies

4. Present product development overviews to potential investors or analysts as needed by Investor Relations

	
1. Knowledge of drug development process

2. Knowledge of regulatory approval requirements

3. Knowledge of individual product characteristics-CMC, nonclinical, clinical

4. Ability to communicate

5. Knowledge of external consultants for review of in-license opportunities

  

- 10 -

  

Exhibit B

 

 

THIS NON-DISCLOSURE, INVENTION AND NON-COMPETITION AGREEMENT (the "Agreement") is effective for all purposes and in all respects, by and between POZEN Inc., a Delaware corporation (hereinafter referred to as "Employer"), and Tomas S. Bocanegra, MD, F.A.C.P., F.A.C.R.  (hereinafter referred to as "Employee").

WHEREAS, Employer is about to employ Employee in a position of trust and confidence to aid Employer in its business; and

WHEREAS, Employer desires to receive from Employee a covenant not to disclose certain information relating to Employer's business and certain other covenants; and

WHEREAS, as a material inducement to Employer to employ Employee and to pay to Employee compensation for such services, Employee has agreed to such covenants; and

WHEREAS, Employer and Employee desire to set forth in writing the terms and conditions of their agreements and understandings.

NOW, THEREFORE, in consideration of the foregoing, of the mutual promises herein contained, and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending legally to be bound, hereby agree as follows:

1.           Disclosure of Information.  Employee acknowledges that, in and as a result of his employment by Employer, he will be making use of, acquiring and/or adding to confidential information of a special and unique nature and value, including, without limitation, Employer's trade secrets, products, systems, programs, procedures, manuals, guides (as periodically updated or supplemented), confidential reports and communications (including, without limitation, customer site information, technical information on the performance and reliability of Employer's products and the development or acquisition of future products or product enhancements by Employer) and lists of customers, as well as the nature and type of the services rendered by Employer and the fees paid by Employer's customers.  Employee further acknowledges that any information and materials received by Employer from third parties in confidence (or subject to non-disclosure covenants) shall be deemed to be and shall be confidential information within the meaning of this Section 1.  As a material inducement to Employer to employ Employee and to pay to Employee compensation for such services to be rendered to Employer by Employee (it being understood and agreed by the parties hereto that such compensation shall also be paid and received in consideration hereof), Employee covenants and agrees that he shall not, except with the prior written consent of the Board of Directors of Employer, at any time during or following the term of his employment with Employer, directly or indirectly, divulge, reveal, report, publish, transfer or disclose, for any purpose whatsoever, any of such confidential information which has been obtained by or disclosed to him as a result of his employment with Employer, including, without limitation, any Proprietary Information, as defined in Section 2 hereof; Employee agrees further that upon termination of his employment

  

- 11 -

  

with Employer for any reason, he shall sign the Employee Termination Statement, a form of which is attached hereto. The aforementioned obligation of confidentiality and non-disclosure shall not apply when:

(a)           Public Domain. The information disclosed to Employee was in the public domain at the time of disclosure, or at any time after disclosure has become a part of the public domain by publication or otherwise through sources other than Employee, directly or indirectly, and without fault on the part of Employee in failing to keep such information confi­dential; or

(b)           Requirement of Law or Order.  Disclosure is required by law or court order, provided Employee gives Employer prior written notice of any such disclosure; or

(c)           Agreement. Disclosure is made with the prior written agreement of the Board of Directors of Employer; or

(d)           Prior Information.  The information is encompassed by the ideas and inventions listed on Schedule A hereto or was in Employee’s possession at the time of disclosure, as shown by written records in existence prior to such time, and such information has not been transferred to Employer, and was not acquired, directly or indirectly, from the Employer; or

(e)           Third Party Disclosure.  The information is lawfully disclosed to Employee after the termination of his employment by a third party who is under no obligation of confidentiality to Employer with respect to such information; or

(f)           Independently Developed.  Such information is independently developed by Employee subsequent to the termination of his active participation in the business of Employer, as demonstrated by written records of Employee which are contemporaneously maintained.

2.           Definition of Proprietary Information.  For purposes of this Agreement, the term "Proprietary Information" shall mean all of the following materials and information (whether or not reduced to writing and whether or not patentable or protectable by copyright) which Employee receives, receives access to, conceives of or develops, in whole or in part, as a direct or indirect result of his employment with Employer, in the course of his employment with Employer (in any capacity, whether executive, managerial, planning, technical, sales, research, development, manufacturing, engineering or otherwise) or through the use of any of Employer's facilities or resources:

(i)           Manufactured products, assembled or unassembled, and any related goods or systems and any and all future products, software or systems developed or derived therefrom;

(ii)           With respect to the items described in Section 2(i) above, all hardware and software relating to design or manufacture; all source and object codes to such hardware and software; all specifications, design concepts, documents and manuals; all security systems relating to the product or procedures, including, without limitation, software security systems;

  

- 12 -

  

(iii)           Trade secrets, production processes, marketing techniques, mailing lists, purchasing information, price lists, pricing policies, quoting procedures, financial information, customer and prospect names and requirements, customer data, customer site information and other materials or information relating to the manner in which Employer does business;

(iv)           Discoveries, concepts and ideas, whether or not patentable or protectable by copyright, including, without limitation, the nature and results of research and development activities, technical information on product or program performance and reliability, processes, formulas, techniques, "know-how", source codes, object codes, designs, drawings and specifications;

(v)           Any other material or information related to the business or activities of Employer which is not generally known to others engaged in similar businesses or activities;

(vi)           Any other material or information that has been created, discovered or developed, or otherwise becomes known to Employer which has commercial value in the business in which Employer is engaged; and

(vii)           All ideas which are derived from or relate to Employee's access to or knowledge of any of the above-enumerated materials and information.

Failure to mark any of the Proprietary Information as confidential shall not affect its status as part of the Proprietary Information under the terms of this Agreement.

3.           Ownership of Information.

(i)           Employee hereby assigns to Employer all of Employee's right, title and interest in any idea (whether or not patentable or protectable by copyright), product, invention, discovery, computer software program or other computer-related equipment or technology, conceived or developed in whole or in part, or in which Employee may have aided in its development, while employed by Employer, including, without limitation, any Proprietary Information.  If any one or more of the aforementioned are deemed in any way to fall within the definition of "work made for hire", as such term is defined in 17 U.S.C. § 101, such work shall be considered "work made for hire", the copyright of which shall be owned solely, completely and exclusively by Employer.  If any of the aforementioned are considered to be work not included in the categories of work covered by the "work made for hire" definition contained in 17 U.S.C. § 101, such work shall be owned solely by, or assigned or transferred completely and exclusively to, Employer.  Employee agrees to execute any instruments and to do all other things reasonably requested by Employer (both during and after Employee's employment with Employer) in order to more fully vest in Employer all ownership rights in those items thereby transferred by Employee to Employer.  Employee further agrees to disclose immediately to Employer all Proprietary Information conceived of or developed in whole or in part by him during the term of his employment with Employer and to assign to Employer any right, title or interest he may have in such Proprietary Information.

  

- 13 -

  

(ii)           Employee hereby represents and warrants that Employee has fully disclosed to Employer on Schedule A hereto any idea, invention, product, improvement, computer software program or other equipment or technology related to therapeutic pharmaceuticals (an “Invention”) not covered in Section 3(i) above which, prior to his employment with Employer, Employee conceived of or developed, wholly or in part, and in which Employee has any right, title or proprietary interest and which directly relate to Employer's business, but which has not been published or filed with the United States Patent or Copyright Offices or assigned or transferred to Employer.  If there is no such list of Schedule A, Employee represents that Employee has made no such Inventions at the time of signing this Agreement or Employee hereby assigns such Inventions to Employer.

(iii)  Notwithstanding anything in this Agreement to the contrary, the obligation of Employee to assign or offer to assign his rights in an Invention to Employer shall not extend or apply to an Invention that Employee developed entirely on his own time without using Employer's equipment, supplies, facility or trade secret information unless such Invention (a) relates to Employer's business or actual or demonstrably anticipated research or development, or (b) results from any work performed by Employee for Employer.  Employee shall bear the burden of proof in establishing that his Invention qualifies for exclusion under this Section 3(iii).  With respect to Section 3(iii), it is agreed and acknowledged that during Employee’s employment, Employer may enter other lines of business, which are related or unrelated to its current lines of business, in which case this Agreement would be expanded to cover such new lines of business.

4.           Injunctive Relief.  Employee understands and agrees that Employer may suffer irreparable harm in the event that Employee breaches any of his obligations under this Agreement and that monetary damages may be inadequate to compensate Employer for such breach.  Accordingly, Employee agrees that, in the event of a breach or threatened breach by Employee of any of the provisions of this Agreement, Employer, in addition to and not in limitation of any other rights, remedies or damages available to Employer at law or in equity, may be entitled to seek a permanent injunction in order to prevent or to restrain any such breach by Employee, or any of employee's partners, agents, representatives, servants, employers, employees and/or any and all persons directly or indirectly acting for or with him.

5.           Records.  All notes, data, tapes, reference materials, sketches, drawings, memoranda, models and records in any way relating to any of the information referred to in Sections 1, 2 and 3 hereof (including, without limitation, any Proprietary Information) or to Employer's business shall belong exclusively to Employer, and Employee agrees to turn over to Employer all such materials and all copies of such materials in his possession or then under his control at the request of Employer or, in the absence of such a request, upon the termination of Employee's employment with Employer.

  

- 14 -

  

6.           Accounting for Profits.  Employee covenants and agrees that, if he shall violate any of his covenants or agreements under this Agreement, Employer may be entitled to seek an accounting and repayment of all profits, compensation, commissions, remunerations or benefits which Employee directly or indirectly has realized and/or may realize as a result of, growing out of or in connection with any such violation; such remedy shall be in addition to and not in limitation of any injunctive relief or other rights or remedies to which Employer is or may be entitled at law, in equity or under this Agreement.

7.           Covenant Not to Compete.  It is recognized and understood by the parties hereto that Employee, through Employee's association with Employer as an employee, shall acquire a considerable amount of knowledge and goodwill with respect to the business of Employer, which knowledge and goodwill are extremely valuable to Employer and which would be extremely detrimental to Employer if used by Employee to compete with Employer.  It is, therefore, understood and agreed by the parties hereto that, because of the nature of the business of Employer, it is necessary to afford fair protection to Employer from such competition by Employee.  Consequently, as a material inducement to employ Employee in the aforementioned positions, Employee covenants and agrees to the following:

(a)           Except as otherwise approved in writing by Employer, Employee agrees:

(i)           that Employee will not, directly or indirectly, with or through any family member or former director, officer or employee of Employer, or acting along or as a member of a partnership or as an officer, holder of or investor in as much as 5% of any security of any class, director, employee, consultant or representative of any corporation or other business entity:

(1) at any time while engaged as an employee of Employer and for a period of two (2) years following termination as an employee, interfere with, or seek to interfere with, the relationship between Employer or any affiliate of Employer and the following: (a) any of the employees of such entities; (b) any of the custom­ers of such entities then existing or existing at any time within three (3) years prior to termination of Employee’s employ­ment by Employer; or (c) any of the suppliers of such entities then existing or existing at any time within three (3) years prior to termination of Employee’s employment by Employer.

(b)           The parties hereto agree that in the event that either the length of time or the geographic area set forth in paragraph (a) is deemed too restrictive in any court proceeding, that the court may reduce such restrictions to those which it deems reasonable under the circumstances.

(c)           Employee agrees and acknowledges that Employer may not have any adequate remedy at law for the breach or threatened breach by him of this covenant and agrees that Employer may in addition to the other remedies which may be available to it under this Agreement, file a suit in equity to enjoin Employee from such breach or threatened breach.

  

- 15 -

  

8.           Reasonableness of Restrictions.

(a)           Employee has carefully read and considered the provisions of Sections 1 through 7 hereof and, having done so, agrees that the restrictions set forth therein are fair and reasonable and are reasonably required for the protection of the interests of Employer, its officers, directors, stockholders and employees.

(b)           In the event that, notwithstanding the foregoing, any part of the covenants set forth in Sections 1 through 7 hereof shall be held to be invalid and unenforceable, the court so deciding may reduce or limit the terms of such provision to allow such provision to be enforced.

9.           Burden and Benefit.  This Agreement shall be binding upon, and shall inure to the benefit of, Employer and Employee, and their respective heirs, personal and legal representatives, and, in the case of Employer, its successors and assigns.

10.           Governing Law.  In view of the fact that the principal office of Employer is located in the State of North Carolina, it is understood and agreed that the construction and interpretation of this Agreement shall at all times and in all respects be governed by the laws of the State of North Carolina.

11.           Severability.  The provisions of this Agreement shall be deemed severable, and the invalidity or unenforceability of any one or more of the provisions hereof shall not affect the validity or enforceability of the other provisions hereof.

12.           Employer.  As used herein, the term "Employer" shall also include any corporation which is at any time the parent or a subsidiary of Employer, or any corporation or entity which is an affiliate of Employer by virtue of common (although not identical) ownership, and for which Employee is providing services in any form during his employment with Employer or any such other corporation or entity.

13.           Notices.  Any notice required to be given hereunder shall be sufficient if in writing, and sent by certified or registered mail, return receipt requested, first-class postage prepaid, in the case of Employee, to his address as shown on Employer's records, and in the case of Employer, to its principal office in the State of North Carolina.

14.           Entire Agreement.  This Agreement contains the entire agreement and understandings by and between Employer and Employee with respect to the covenants herein described, and no representations, promises, agreements or understandings, written or oral, not herein contained shall be of any force or effect.  Nothing contained in this Agreement shall be deemed or construed to constitute an agreement by Employer to employ or continue to employ Employee.  No change or modification hereof shall be valid or binding unless the same is in writing and signed by the parties hereto.  No waiver of any provision of this Agreement shall be valid unless the same is in writing and signed by the party against whom such waiver is sought to be enforced; moreover, no valid waiver of any provision of this Agreement at any time shall be deemed a waiver of any other provision of this Agreement at such time nor will it be deemed a valid waiver of such provision at any other time.

  

- 16 -

  

15.           Headings.  The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement.

16.           Effective Date.  This Agreement shall be effective as of the date July 5, 2011.

IN WITNESS WHEREOF, Employer and Employee have duly executed this Agreement as of the day and year first above written.

EMPLOYER:

	
POZEN Inc.

	  
	  	  	  
	  	
By:

	  
	  	
Name:

	
John E. Barnhardt

	  	
Title:

	
Vice President, Finance and Administration

EMPLOYEE:

	  	  	  	  
	  	
Tomás S. Bocanegra, MD, F.A.C.P., F.A.C.R.

	  	
Date

  

- 17 -

  

SCHEDULE A

Inventions, Ideas, Products, Etc. Not Covered in Section 3(i) of the Agreement

[Note:  If Employee has no such items to disclose, write "NONE" on this line:  ___________.]

  

- 18 -

  

EMPLOYEE TERMINATION STATEMENT

1.            I am cognizant of my legal obligations, as stated in that certain Non-Disclosure, Invention and Non-Competition Agreement, dated _________, 2___, which I signed at the commencement of my employment with respect to confidential information of POZEN Inc. (the "Company"), and hereby specifically reaffirm all of the provisions stated therein.

2.           I understand that my obligation not to use or disclose Company confidential information remains in effect after the termination of my employment with the Company and that if, at any time in the future, I wish to utilize, disclose or publish any Company confidential information, or if I should be in doubt as to whether any such information may be confidential to the Company, I will, prior to such use or disclosure, obtain the written consent of the Company to do so.  I further understand that such consent may be refused where Company confidential information is involved.

3.           I understand that, to the extent permitted by law, any idea, invention, discovery, computer software program or other computer-related equipment or technology, conceived or developed by me in whole or in part, or in which I may have aided in its development during my employment with the Company, belongs exclusively to the Company except as excluded by the above referenced Non-Disclosure, Invention and Non-Competition Agreement.  I hereby certify that I have made full disclosure in writing to the Company or have discussed with my supervisor at the Company all of such ideas, inventions, discoveries, computer programs and computer-related equipment or technology.  I further understand that I still have an obligation subsequent to termination of my employment with the Company to execute such papers as the Company may reasonably request to more fully vest in the Company all ownership rights in the items referenced in this paragraph.

4.           I hereby certify that all materials related directly or indirectly to my employment with the Company and all copies thereof, have been returned to my supervisor at the Company.  I further certify that no computer listings, programs, object codes, source codes, product development guides, flow-charts or other documents owned by the Company or provided to or used by me in connection with my employment at the Company, whether in machine-readable form or otherwise, have been retained by me or given to any other third person or entity in anticipation of my employment termination or for any other reason, and further certify that none of the aforementioned will be removed from the Company's premises by me.

ACCEPTED:

	
POZEN Inc.

	  	  	  
	  	  	  	  	  
	
By:

	  	  	  	  
	  	  	  	  	  
	
Date:

	  	  	
Date:

	  

  

- 19 -

  

EXHIBIT C

Offer Letter

May 27, 2011

May 27, 2011

Tomas S. Bocanegra, MD, F.A.C.P., F.A.C.R.

1061 Lawrence Avenue

Westfield, NJ 07090

Dear Dr. Bocanegra:

I am pleased to offer you the position of Executive Vice President, Development at POZEN Inc.  This is a full time position reporting to the President and CEO. This offer is subject to your commitment to a start date of July 5, 2011 and contingent upon your agreement to the terms set forth in this letter and the enclosed Nondisclosure, Invention and Non-Competition Agreement.  Attached are a description of our compensation offer (Exhibit A) and a listing of initial responsibilities to be assumed by you as the Executive Vice President, Development (Exhibit B), which are hereby made a part of this employment offer.

This position, and your employment with POZEN should you accept this offer, is “at will”.  This means that, just as you may resign your employment at any time, POZEN may, in its sole discretion, with or without cause, terminate your employment at any time for any reason.  You and your supervisor should communicate regularly to discuss expectations, performance, concerns, and progress toward meeting objectives.  You will hold in a fiduciary capacity for the benefit of the Company all information with respect to the Company’s finances, sales, profits, and other proprietary and confidential information acquired by you during your employment.  In furtherance of this condition of your employment, we would kindly request that you sign the enclosed Nondisclosure, Invention and Non-Competition Agreement.

Upon termination of your employment with the Company and prior to your departure from the Company, you agree to submit to an exit interview for the purposes of reviewing this letter agreement, the enclosed Nondisclosure, Invention and Non-Competition Agreement and the trade secrets of the Company, and surrendering to the Company all proprietary or confidential information and articles belonging to the Company.

By your signature below, you represent and warrant to the Company that you are not subject to any employment, noncompetition or other similar agreement that would prevent or interfere with the Company’s employment of you on the terms set forth herein.

  

- 20 -

  

This letter agreement, the Nondisclosure, Invention and Non-Competition Agreement and all ancillary agreements (collectively, the “Agreements”) shall be governed by the laws of the State of North Carolina.  The Agreements constitute the entire agreement between the Company and you, and supersede any and all previous oral or written representation, communication, understanding or agreement between us. Any and all changes or amendments to the Agreements shall be made in writing and signed by the parties.

I hope that you will accept this offer and join our POZEN team.  Please contact me by June 1, 2011 regarding your acceptance of this offer.  A copy of this letter should be signed and returned to me at your earliest convenience to confirm your acceptance.

Sincerely,

John R. Plachetka, Pharm.D.

Chairman, President and Chief Executive Officer

I accept the position offered to me by POZEN Inc., and the terms and conditions related thereto as outlined above.

____________________________________                                                                      _____________________________

Tomas S. Bocanegra, MD, F.A.C.P., F.A.C.R.                                                                           Date

  

- 21 -

  

Exhibit A

Your full time annualized base salary rate will be $385,000.

In addition, you will have the annual opportunity, effective commencing the fiscal year 2011, to earn a bonus, subject to the completion of agreed upon corporate objectives, with a target of 40% of your eligible base salary earnings, such bonus to be determined in the discretion of the CEO and, subject to approval by the Compensation Committee or the Board of Directors, an annual stock option or other incentive award.

You will also receive, upon commencing employment at POZEN, an option to purchase 100,000 shares of POZEN stock, which will vest 25% each anniversary of the grant date, under POZEN’s current Stock Option Plan.

In order to facilitate your move to North Carolina, you will also receive, upon commencing employment at POZEN, the following:

 

1 - A one-time $50,000 sign on bonus to help cover incidental out of pocket costs:

	
·  

	
$25,000 to be paid upon commencing employment at POZEN.

	
·  

	
$25,000 to be paid six months after commencing employment at POZEN.

2 – Reimbursements up to $100,000 to cover:

	
·  

	
The closing costs (including realtor's commission) on the sale of your existing home.

	
·  

	
The packing, moving, insuring and unpacking of household goods into your existing North Carolina home and into your rental property in the Chapel Hill area.

	
·  

	
Actual costs of your physical move to begin employment (car mileage, on route meal and lodging costs, shipment of car, etc.).

In addition, POZEN will reimburse you for the direct out of pocket costs of up to 7 days of house hunting to assist you in securing a rental property in the Chapel Hill area.  Appropriate out of pocket costs include air fare, rental car, hotel, and reasonable meal costs for you and your family.

 

POZEN will also reimburse you for up to 60 days of out of pocket costs related to temporary living.  This covers the period between your first date of employment and the time you move into your new rental property in the Chapel Hill area.  Appropriate costs to be reimbursed are reasonable expenses for corporate apartment or hotel; rental car if needed; meals, laundry, etc.

  

- 22 -

  

Both the one-time sign on payment of $50,000 and the relocation reimbursement will require your execution of a note, payable to POZEN, for the one-time sign on payment of $50,000 and any amount paid to you, or on your behalf, as a relocation reimbursement.  If you terminate your employment at POZEN at anytime prior to twenty-four months from your start date, the note will become due in full at that date.  The note will be forgiven twenty-four months from your start date if you have been continually employed at POZEN on that date.  Your death, disability or involuntary termination, other than for Cause, will result in the cancellation of the note.

  

- 23 -Exhibit 10.1

 

SECOND AMENDMENT TO FOURTH AMENDED AND RESTATED

CREDIT AGREEMENT

 

This SECOND AMENDMENT TO FOURTH AMENDED AND RESTATED CREDIT AGREEMENT  (this “Amendment”) is made as of July 8, 2011, by and among ANTERO RESOURCES CORPORATION, a Delaware corporation (“Antero”), ANTERO RESOURCES PICEANCE CORPORATION, a Delaware corporation (“Antero Piceance”), ANTERO RESOURCES PIPELINE CORPORATION, a Delaware corporation (“Antero Pipeline”), and ANTERO RESOURCES APPALACHIAN CORPORATION, a Delaware corporation (“Antero Appalachian” and, together with Antero, Antero Piceance and Antero Pipeline, each, a “Borrower” and collectively, the “Borrowers”), CERTAIN SUBSIDIARIES OF BORROWERS, as Guarantors, the LENDERS party hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent (in such capacity, the “Administrative Agent”).  Unless otherwise expressly defined herein, capitalized terms used but not defined in this Amendment have the meanings assigned to such terms in the Credit Agreement (as defined below).

 

WITNESSETH:

 

WHEREAS, the Borrowers, the Guarantors, the Administrative Agent and the Lenders have entered into that certain Fourth Amended and Restated Credit Agreement, dated as of November 4, 2010 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”); and

 

WHEREAS, the Administrative Agent, the Lenders, the Borrowers and the Guarantors have agreed to amend the Credit Agreement as provided herein subject to the terms and conditions set forth herein.

 

NOW, THEREFORE, for and in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and confessed, the Borrowers, the Guarantors, the Administrative Agent and the Lenders hereby agree as follows:

 

SECTION 1.                            Amendments to Credit Agreement.  Subject to the satisfaction or waiver in writing of each condition precedent set forth in Section 2 of this Amendment, and in reliance on the representations, warranties, covenants and agreements contained in this Amendment, the Credit Agreement shall be amended in the manner provided in this Section 1.

 

1.1               Amended Definition.  The following definition in Section 1.01 of the Credit Agreement shall be and it hereby is amended and restated in its entirety to read as follows:

 

“EBITDAX” means, with respect to any Person for any period, Consolidated Net Income for such period; plus without duplication and to the extent deducted in the calculation of Consolidated Net Income for such period, the sum of (a) any provision for (or less any benefit for) income or franchise Taxes; (b) Consolidated Interest Expense; (c) amortization, depletion, depreciation and exploration expense; and (d) any non-cash losses, expenses, impairments or charges (including losses arising from ceiling test writedowns,

 

 

non-cash losses or charges resulting from the requirements of SFAS 123, 123R, 133 or 143, but excluding accruals of or reserves for cash charges for any future period); provided that cash payments made during such period or in any future period in respect of non-cash charges, expenses or losses, other than any such excluded charge, expense or loss described in the parenthetical to this clause (d) shall be subtracted from Consolidated Net Income in calculating EBITDAX for the period in which such payments are made; minus, to the extent included in the calculation of Consolidated Net Income, the sum of (i) interest income, (ii) any extraordinary income or gains; and (iii) any other non-cash income or gain, including non-cash income or gains resulting from the requirements of SFAS 123, 123R, 133 or 143, but excluding any items that represent the reversal of any accrual of, or cash reserve for, anticipated cash charges in any prior period that are described in clause (d) above; provided that, with respect to the determination of Holdings’ compliance with the Interest Coverage Ratio set forth in Section 7.12 for any period, EBITDAX for such period shall be adjusted to give effect, on a pro forma basis and consistent with GAAP, to any Acquisitions or Dispositions made during such period as if such Acquisition or Disposition, as the case may be, was made at the beginning of such period.

 

1.2               Additional Definitions.  The following definitions shall be and they hereby are added to Section 1.01 of the Credit Agreement in appropriate alphabetical order:

 

“Consolidated Interest Expense” means for any period, without duplication, the aggregate of all interest expense of Holdings and its Consolidated Subsidiaries that are Credit Parties as determined in accordance with GAAP, including (a) all interest, fees and costs payable with respect to the Indebtedness of such Persons to the extent treated as interest in accordance with GAAP (other than fees and costs which may be capitalized as transaction costs in accordance with GAAP) and (b) the interest component of Capital Lease Obligations, to the extent treated as interest in accordance with GAAP.

 

“Interest Coverage Ratio” means, with respect to any fiscal quarter, the ratio of (i) the sum of the Consolidated EBITDAX of Holdings for the trailing four fiscal quarter period ending on the last day of such fiscal quarter to (ii) the sum of the Consolidated Interest Expense of Holdings for the trailing four fiscal quarter period ending on the last day of such fiscal quarter.

 

1.3                   Deleted Definition.  The defined term “Leverage Ratio” located in Section 1.01 of the Credit Agreement shall be and it hereby is deleted in its entirety.

 

1.4                               Interest Coverage Ratio.  Section 7.12 of the Credit Agreement shall be and it hereby is amended and restated in its entirety to read as follows:

 

Section 7.12                            Interest Coverage Ratio.  At the end of each fiscal quarter ending on or after June 30, 2011, the Interest Coverage Ratio will not be less than 2.50 to 1.0.

 

 

SECTION 2.                            Conditions.  The amendments to the Credit Agreement contained in Section 1 of this Amendment shall be effective upon the satisfaction of each of the conditions set forth in this Section 2.

 

2.1               Execution and Delivery.  Each Credit Party, the Majority Lenders, and the Administrative Agent shall have executed and delivered this Amendment.

 

2.2               No Default.  No Default shall have occurred and be continuing or shall result from the effectiveness of this Amendment.

 

2.3               Other Documents.  The Administrative Agent shall have received such other instruments and documents incidental and appropriate to the transaction provided for herein as the Administrative Agent or its special counsel may reasonably request, and all such documents shall be in form and substance reasonably satisfactory to the Administrative Agent.

 

SECTION 3.                            Representations and Warranties of Credit Parties.  To induce the Lenders to enter into this Amendment, each Credit Party hereby represents and warrants to the Lenders as follows:

 

3.1               Reaffirmation of Representations and Warranties/Further Assurances.  After giving effect to the amendments herein, each representation and warranty of such Credit Party contained in the Credit Agreement and in each of the other Loan Documents is true and correct in all material respects as of the date hereof (except to the extent such representations and warranties specifically refer to an earlier date, in which case they are true and correct in all material respects as of such earlier date).

 

3.2               Corporate Authority; No Conflicts.  The execution, delivery and performance by each Credit Party of this Amendment are within such Credit Party’s corporate or other organizational powers, have been duly authorized by necessary action, require no action by or in respect of, or filing with, any court or agency of government and do not violate or constitute a default under any provision of any applicable law or other agreements binding upon any Credit Party or result in the creation or imposition of any Lien upon any of the assets of any Credit Party except for Permitted Liens and otherwise as permitted in the Credit Agreement.

 

3.3               Enforceability.  This Amendment constitutes the valid and binding obligation of the Borrowers and each other Credit Party enforceable in accordance with its terms, except as (i) the enforceability thereof may be limited by bankruptcy, insolvency or similar laws affecting creditor’s rights generally, and (ii) the availability of equitable remedies may be limited by equitable principles of general application.

 

3.4               No Default.  As of the date hereof, both before and immediately after giving effect to this Amendment, no Default has occurred and is continuing.

 

 

SECTION 4.                            Miscellaneous.

 

4.1               Reaffirmation of Loan Documents and Liens.  Any and all of the terms and provisions of the Credit Agreement and the Loan Documents shall, except as amended and modified hereby, remain in full force and effect and are hereby in all respects ratified and confirmed by each Credit Party.  Each Borrower and each Guarantor hereby agree that the amendments and modifications herein contained shall in no manner affect or impair the liabilities, duties and obligations of any Credit Party under the Credit Agreement and the other Loan Documents or the Liens securing the payment and performance thereof.

 

4.2               Parties in Interest.  All of the terms and provisions of this Amendment shall bind and inure to the benefit of the parties hereto and their respective successors and assigns.

 

4.3               Legal Expenses.  Each Credit Party hereby agrees to pay all reasonable fees and expenses of special counsel to the Administrative Agent incurred by the Administrative Agent in connection with the preparation, negotiation and execution of this Amendment and all related documents.

 

4.4               Counterparts.  This Amendment may be executed in one or more counterparts and by different parties hereto in separate counterparts each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument; signature pages may be detached from multiple separate counterparts and attached to a single counterpart so that all signature pages are physically attached to the same document.  Delivery of photocopies of the signature pages to this Amendment by facsimile or electronic mail shall be effective as delivery of manually executed counterparts of this Amendment.

 

4.5               Complete Agreement.  THIS AMENDMENT, THE CREDIT AGREEMENT, AND THE OTHER LOAN DOCUMENTS REPRESENT THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS OR ORAL AGREEMENTS OF THE PARTIES.  THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.

 

4.6               Headings.  The headings, captions and arrangements used in this Amendment are, unless specified otherwise, for convenience only and shall not be deemed to limit, amplify or modify the terms of this Amendment, nor affect the meaning thereof.

 

4.7               Governing Law.  This Amendment shall be construed in accordance with and governed by the laws of the State of New York.

 

4.8               Loan Document.  This Amendment shall constitute a Loan Document for all purposes and in all respects.

 

[Remainder of page intentionally blank.

Signature pages follow.]

 

 

IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed by their respective authorized officers to be effective as of the date first above written.

 

	
 
    	
BORROWERS:
    
	
 
    	
 
    
	
 
    	
ANTERO   RESOURCES CORPORATION
    
	
 
    	
 
    
	
 
    	
ANTERO   RESOURCES PICEANCE CORPORATION
    
	
 
    	
 
    
	
 
    	
ANTERO   RESOURCES PIPELINE CORPORATION
    
	
 
    	
 
    
	
 
    	
ANTERO   RESOURCES APPALACHIAN CORPORATION
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Alvyn A. Schopp
    
	
 
    	
 
    	
Name:
    	
Alvyn   A. Schopp
    
	
 
    	
 
    	
Title:
    	
Treasurer   and Vice President,
    
	
 
    	
 
    	
 
    	
Administration   and Accounting
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
RESTRICTED   SUBSIDIARIES:
    
	
 
    	
 
    
	
 
    	
ANTERO   RESOURCES FINANCE CORPORATION
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Alvyn A. Schopp
    
	
 
    	
 
    	
Name:
    	
Alvyn   A. Schopp
    
	
 
    	
 
    	
Title:
    	
Treasurer   and Vice President,
    
	
 
    	
 
    	
 
    	
Administration   and Accounting
    
	
 
    	
 
    
	
 
    	
ANTERO   RESOURCES BLUESTONE LLC
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
s/   Alvyn A. Schopp
    
	
 
    	
 
    	
Name:   
    	
Alvyn   A. Schopp
    
	
 
    	
 
    	
Title:
    	
Vice   President — Accounting &
   Administration/Treasurer
    

 

 

	
 
    	
JPMORGAN   CHASE BANK, N.A.,
    
	
 
    	
as   Administrative Agent, Issuing Bank and a Lender
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Brian Orlando
    
	
 
    	
 
    	
Name:
    	
Brian   Orlando
    
	
 
    	
 
    	
Title:
    	
Authorized   Officer
    

 

 

	
 
    	
WELLS   FARGO BANK, N.A.,
    
	
 
    	
as   Syndication Agent and a Lender
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Oleg Kogan
    
	
 
    	
 
    	
Name:
    	
Oleg   Kogan
    
	
 
    	
 
    	
Title:
    	
Director
    

 

 

	
 
    	
BANK   OF SCOTLAND PLC,
    
	
 
    	
as   Co-Documentation Agent and a Lender
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Julia R. Franklin
    
	
 
    	
 
    	
Name:
    	
Julia   R. Franklin
    
	
 
    	
 
    	
Title:
    	
Assistant   Vice President
    

 

 

	
 
    	
BNP   PARIBAS,
    
	
 
    	
as   Co-Documentation Agent and a Lender
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Russell Otts
    
	
 
    	
 
    	
Name:
    	
Russell   Otts
    
	
 
    	
 
    	
Title:
    	
Director
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Matt Turner
    
	
 
    	
 
    	
Name:
    	
Matt   Turner
    
	
 
    	
 
    	
Title:
    	
Vice   President
    

 

 

	
 
    	
CREDIT   AGRICOLE CORPORATE AND INVESTMENT BANK,
    
	
 
    	
as   Co-Documentation  Agent and  a Lender
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Mark A. Roche
    
	
 
    	
 
    	
Name:
    	
Mark   A. Roche
    
	
 
    	
 
    	
Title:
    	
Managing   Director
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Sharada Manne
    
	
 
    	
 
    	
Name:
    	
Sharada   Manne
    
	
 
    	
 
    	
Title:
    	
Director
    

 

 

	
 
    	
DEUTSCHE   BANK TRUST COMPANY AMERICAS,
    
	
 
    	
as   Co-Documentation Agent and a Lender
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Michael Getz
    
	
 
    	
 
    	
Name:
    	
Michael   Getz
    
	
 
    	
 
    	
Title:
    	
Vice   President
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Evelyn Thierry
    
	
 
    	
 
    	
Name:
    	
Evelyn   Thierry
    
	
 
    	
 
    	
Title:
    	
Director
    

 

 

	
 
    	
UNION BANK, N.A.,
    
	
 
    	
as Co-Documentation Agent   and  a Lender
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Jarrod Bourgeois
    
	
 
    	
 
    	
Name:
    	
Jarrod   Bourgeois
    
	
 
    	
 
    	
Title:
    	
Vice   President
    

 

 

	
 
    	
BARCLAYS   BANK PLC,
    
	
 
    	
as   a Lender
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Vanessa A. Kurbatskiy
    
	
 
    	
 
    	
Name:
    	
Vanessa   A. Kurbatskiy
    
	
 
    	
 
    	
Title:   
    	
Vice   President
    

 

 

	
 
    	
COMERICA   BANK,
    
	
 
    	
as   a Lender
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Paul J. Edmonds
    
	
 
    	
 
    	
Name:   
    	
Paul   J. Edmonds
    
	
 
    	
 
    	
Title:   
    	
VicePresident
    

 

 

	
 
    	
CREDIT   SUISSE AG, CAYMAN ISLANDS BRANCH,
    
	
 
    	
as   a Lender
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Nupur Kumar
    
	
 
    	
 
    	
Name:   
    	
Nupur   Kumar
    
	
 
    	
 
    	
Title:   
    	
Vice   President
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Rahul Parmar
    
	
 
    	
 
    	
Name:   
    	
Rahul   Parmar
    
	
 
    	
 
    	
Title:   
    	
Associate
    

 

 

	
 
    	
KEY   BANK NATIONAL ASSOCIATION,
    
	
 
    	
as   a Lender
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   David Morris
    
	
 
    	
 
    	
Name:   
    	
David   Morris
    
	
 
    	
 
    	
Title:   
    	
Vice   President
    

 

 

	
 
    	
U.S.   BANK NATIONAL ASSOCIATION,
    
	
 
    	
as   a Lender
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Name:
    
	
 
    	
 
    	
Title:
    

 

 

	
 
    	
GUARANTY   BANK AND TRUST COMPANY,
    
	
 
    	
as   a Lender
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Gail J. Nofsinger
    
	
 
    	
 
    	
Name:   
    	
Gail   J. Nofsinger
    
	
 
    	
 
    	
Title:   
    	
Senior   Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}]]